|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1966-01-01 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段药物发现 |
首次获批国家/地区- |
首次获批日期- |
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.
100 项与 AlzProtect SAS 相关的临床结果
0 项与 AlzProtect SAS 相关的专利(医药)
100 项与 AlzProtect SAS 相关的药物交易
100 项与 AlzProtect SAS 相关的转化医学